MedPath

Preparation for Medical and Surgical Procedures in Oncogeriatry.

Not Applicable
Recruiting
Conditions
Geriatric Oncology
Interventions
Other: Personalized pre-habilitation program
Registration Number
NCT06443138
Lead Sponsor
Centre Hospitalier Universitaire de Nice
Brief Summary

Surgical management is one of the most frequently used interventions in the treatment of many cancers, but it can be associated with a high risk of postoperative complications.

The maintenance and optimization of functional abilities before, during and after treatment are major for elderly cancer patients, as it is now well established that there is a link between the level of functional capacity and the occurrence of these complications.

The scientific literature shows that the benefits of pre- and post-operative training programs, but these benefits only apply to a fraction of the patients adhering to the programs. The modalities of intervention (training load, follow-up, etc.) as well as patient involvement in these programs are major issues that need to be addressed to optimize their benefits.

Individualizing pre-habilitation, on the basis of the management of the training load, and therefore objective fatigue, would enable better patient adherence to the program, and optimize its benefits.

In this context, the PRIMECHO project aims to individualize pre-habilitation in order to improve functional of patients in the pre-habilitation or accelerated recovery after surgery phase. The aim is for the patient to be in optimum physical condition at the time of the intervention or treatment.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Patient aged 70 or over
  • Cancer patient with planned surgery,
  • Mini Mental State Examination score greater than or equal to 24 (performed in advance by the geriatrician),
  • Patient affiliated to or benefiting from a social security insurance
  • Signed free and informed consent.
Exclusion Criteria
  • Inability to walk or perform unsupervised exercises.
  • Vulnerable people

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Personalized pre-habilitation programPersonalized pre-habilitation program-
Primary Outcome Measures
NameTimeMethod
Maximal walking distance to 6 -MWTat 16 weeks

Metres walked during the test

Secondary Outcome Measures
NameTimeMethod
Fatigue scale (MFI-20)at inclusion, 4 weeks, 8 weeks, 16 weeks

Multidiensional Fatigue Inventory-20 (MFI-20) questionnaire. 5 scales. Higher scores means worse outcome.

General Fatigue dimension: Minimum value: 4. Maximum Value: 20. Physical fatigue dimension: Minimum value: 4. Maximum Value: 20. Reduced activity dimension: Minimum value: 4. Maximum Value: 20. Reduced motivation dimension: Minimum value: 4. Maximum Value: 20. Mental fatigue dimension: Minimum value: 4. Maximum Value: 20.

Internationnal Physiqual activity questionaire (IPAQ-short)at inclusion, 4 weeks, 8 weeks, 16 weeks

This questionnaire assesses overall physical activity and sedentary time over the last seven days. The questionnaire looks at intense, moderate and walking activity, as well as time spent sitting down (sedentary lifestyle), whether during leisure activities, at work, in daily life or during transport.

The questionnaire composed with 7 questions classifies the subject according to 3 levels of activity: inactive, moderate, high.

EORTC-QLQC30at inclusion, 4 weeks, 8 weeks, 16 weeks

QLQC30 is a 30-item instrument designed to measure quality of life in all cancer patients.

It contains 30 questions and assesses the quality of life of oncological patients multidimensionally over 10 subscales. All sub-scales and the 6 individual items have a score range from 0 to 100 points. A higher score represents better function and a higher quality of life. In the symptom subscale, however, a higher score represents a higher level of symptoms or problems. Since there is no total score, all subscales and the individual items must be considered individually and evaluated using normative data.

Trial Locations

Locations (1)

CHU de Nice

🇫🇷

Nice, France

© Copyright 2025. All Rights Reserved by MedPath